Jabbit

News explainer · Sources checked October 15, 2026

Published · Updated

Wegovy HD (7.2 mg): what FDA approved

On March 19, 2026, FDA approved a higher 7.2 mg dose of Wegovy (semaglutide), called Wegovy HD, for weight reduction and long-term maintenance in adults with obesity, or overweight with at least one weight-related condition.[1]

Review speed

FDA said the decision came 54 days after filing and was the fourth approval under the Commissioner’s National Priority Voucher pilot program, which offers enhanced communication and rolling review.[1]

What the data showed

According to FDA, the higher dose produced additional average weight reduction compared with previously approved doses. In people with obesity and type 2 diabetes, HbA1c lowering was similar to the lower dose. The most common adverse reactions were gastrointestinal. Altered skin sensation (sensitivity, pain, or burning) was common, occurred more often at the higher dose, and FDA said it is investigating this further.[1]

Boxed warning

Wegovy carries a boxed warning about thyroid C-cell tumors based on rodent findings and should not be used by people with a personal or family history of medullary thyroid carcinoma or MEN 2.[1]

References

  1. U.S. Food and Drug Administration. FDA Approves Fourth Product Under National Priority Voucher Program: Higher-Dose Semaglutide. Press announcement, March 19, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-fourth-product-under-national-priority-voucher-program-higher-dose-semaglutide. Checked October 15, 2026.
  2. U.S. Food and Drug Administration. Wegovy (semaglutide) injection, NDA 215256 approval letter, June 4, 2021. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215256Orig1s000Approv.pdf. Checked October 15, 2026.

This page summarizes published research and regulatory documents. It is not medical advice and does not recommend starting, stopping, or changing any medication.